Our validated preclinical platform employs genetically engineered murine models, including ApoE-/- and LDLR-/- knockout strains, that accurately recapitulate human cardiovascular pathophysiology to generate translational data for therapeutic development. These well-characterized models undergo comprehensive phenotypic characterization under controlled dietary regimens, enabling precise evaluation of candidate compounds' effects on atherogenesis, plaque stability, and systemic lipid metabolism with high clinical relevance.
Genetic Modification Models
Preclinical Services
Ace Therapeutics is a contract research organization focused on advancing cardiovascular therapeutics through integrated discovery and development solutions.
Ace Therapeutics owns a preclinical imaging platform to help researchers detect cardiovascular disease states and evaluate drug efficiency.
Ace Therapeutics offers comprehensive solutions and R&D services to researchers worldwide to advance the field of cardiovascular diseases.
We do not provide medical care for patients.
Copyright © Ace Therapeutics. All rights reserved.